[ { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#Head", "@graph": [ { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#pubInfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] }, { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#provenance", "@graph": [ { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#assertion", "http://www.w3.org/ns/prov#generatedAtTime": [ { "@value": "2021-08-26T09:18:29.198055", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ] } ] }, { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#assertion", "@graph": [ { "@id": "http://purl.obolibrary.org/obo/DOID_1574", "@type": [ "https://w3id.org/biolink/vocab/Disease" ] }, { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#association", "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [ { "@id": "http://purl.obolibrary.org/obo/DOID_1574" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [ { "@id": "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [ { "@id": "https://identifiers.org/DRUGBANK:DB00334" } ], "@type": [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers." } ], "https://w3id.org/biolink/vocab/has_population_context": [ { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#context" } ], "https://w3id.org/biolink/vocab/provided_by": [ { "@id": "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/publications": [ { "@id": "https://pubmed.ncbi.nlm.nih.gov/29912214" } ], "https://w3id.org/biolink/vocab/relation": [ { "@id": "https://w3id.org/um/neurodkg/OffLabelIndication" } ] }, { "@id": "https://identifiers.org/DRUGBANK:DB00334", "@type": [ "https://w3id.org/biolink/vocab/Drug" ] }, { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#context", "@type": [ "https://w3id.org/biolink/vocab/Cohort" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "adults" } ] } ] }, { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#pubInfo", "@graph": [ { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "Xul0Er1OEZlq+dVjbQ0m1pCd5STdOYyyHJARC23oqe/5lhRL5V1pr6zj39fii3udiM/oFfnA67tJ2ToNRVXdbaWJ1UlSjx04RpgdSwAQUQcNm57ILUyuwyImpyCBmkQ4q1t5r9ie/+FSFHAXAtrok87vzn6Aarb0u4QuYXZyhV4=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4" } ] }, { "@id": "http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4", "http://www.w3.org/ns/prov#generatedAtTime": [ { "@value": "2021-08-26T09:18:29.198055", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-7641-6446" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] } ] } ]